Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Chugai Pharmaceutical Co., Ltd. (Japan)

ClinicalTrials.gov lists Chugai Pharmaceutical Co., Ltd. (Japan) as lead sponsor of 63 trials. It has 19 active development programs and 23 approved assets.

JP Industry
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

11 0 1999 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 5 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 4 in 2026 and about 5 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 5 already registered with a 2026 start date: at the cutoff, 2 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

This page covers Chugai Pharmaceutical Co., Ltd. (Japan): 63 lead-sponsored trials and 3 legal-entity registrations.

Get the Chugai Pharmaceutical Co., Ltd. (Japan) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (72)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Arthritis, Rheumatoid 12
Breast Neoplasms 10
Anemia 7
Hemophilia A 7
Lung Neoplasms 7

Trials by start year as sponsor or collaborator (25)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 5
2025 6
2024 5
2023 5
2022 7
2021 11
2020 8
2019 2
2018 2
2017 1

Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 51 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (19)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
DONQ52 Celiac Disease Phase 2 2
RAY121 Hemorrhage Phase 1 2
RAY121 Myositis Phase 1 2
RAY121 Pemphigoid, Bullous Phase 1 2
RAY121 Dermatomyositis Phase 1 2

Approved assets (23)

Shown in this order: max phase first.

Approved assets
Drug Trials
PEGinterferon alfa-2a 2
Tocilizumab 13
Methoxy Polyethylene Glycol-Epoetin Beta 6
EPOETIN ALFA 2
METHOTREXATE 2

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
40% hit target (n=15) 60% on time (n=15)

Journals published in (62)

Shown in this order: most published in first.

Journals published in
Journal Publications
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 7
The New England journal of medicine 5
The Journal of rheumatology 4
Blood 3
Fertility and sterility 3

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
17 1 2023-10-31

FDA import refusals (1)

FDA import refusals
Refused import lines Latest refusal
1 2008-08-14

Organization relationships (18)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
The Japan Lung Cancer Society Co sponsors trial with 3
Roche (Switzerland) Co sponsors trial with 2
Institut Bergonié Co sponsors trial with 1
French Innovative Leukemia Organization Co sponsors trial with 1
Keio University Co sponsors trial with 1

Latest dated events (135)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-11-30 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-11-15 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-24 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-05-15 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-04-27 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (313)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABR Trial collaborator Primary endpoint in a Phase 3 trial
ABR Trial collaborator Primary endpoint in a Phase 3 trial
ABR Trial collaborator Primary endpoint in a Phase 3 trial
ABR Trial collaborator Primary endpoint in a Phase 3 trial
ADPRS Trial collaborator Named in trial inclusion criteria

On Scientist.com

Chugai Pharmaceutical Co., Ltd. (Japan) is listed as a research supplier in the Scientist.com network.

Source: Scientist.com supplier network

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.

Work with Chugai Pharmaceutical Co., Ltd. on Scientist.com

For prices, more details, or to contact Chugai Pharmaceutical Co., Ltd., visit Scientist.com.

Sign in to Scientist.com to open this supplier in your organization's marketplace.